Physician profile
Robert Toltzis
NPI 1265480677
$6,602.41
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $571 · 2020: $932 · 2021: $1,201 · 2022: $1,320 · 2023: $1,395 · 2024: $1,183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,578.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,578.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,812.27 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $1,127.81 | 2019-2024 | |
| Amgen INC. | $820.53 | 2019-2024 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $752.07 | 2019-2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $434.58 | 2020-2024 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals LP | $362.40 | 2019-2024 | Wainua, Farxiga |
| Medtronic, INC. | $201.48 | 2022 | |
| Pfizer INC. | $127.11 | 2019-2023 | |
| Boston Scientific Corporation | $112.62 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $108.30 | 2019-2024 | |
| Scpharmaceuticals INC. | $93.28 | 2023-2024 | |
| Esperion Therapeutics, INC. | $78.24 | 2021-2024 | Nexletol |
| Amarin Pharma, INC. | $74.90 | 2020-2022 | |
| Lundbeck LLC | $55.59 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $44.40 | 2022-2024 | Verquvo |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $43.47 | 2019-2024 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $42.74 | 2024 | |
| Chiesi USA, INC. | $33.84 | 2020-2023 | Kengreal |
| Kiniksa Pharmaceuticals, LTD. | $31.17 | 2022-2023 | Arcalyst |
| Novo Nordisk INC | $29.48 | 2023-2024 | Ozempic, Rybelsus |
| Regeneron Healthcare Solutions, INC. | $27.23 | 2019-2022 | |
| Akcea Therapeutics, INC. | $22.01 | 2020 | |
| Daiichi Sankyo INC. | $21.14 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $19.82 | 2024 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $18.54 | 2021 | |
| Abbott Laboratories | $17.21 | 2021 | |
| Astellas Pharma US INC | $16.27 | 2021 | |
| Braemar Manufacturing, LLC | $15.68 | 2019 | |
| Vifor Pharma, INC. | $15.09 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.81 | 2019 | |
| Gilead Sciences, INC. | $10.91 | 2019 | |
| Itamar Medical INC | $10.38 | 2024 | Watchpatone |
| Actelion Pharmaceuticals US, INC. | $8.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Toltzis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.